Afinitor and Myelosuppression - a phase IV clinical study of FDA data

Summary:

Myelosuppression is reported as a side effect among people who take Afinitor (everolimus), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Combivent, and have Pancreatic neuroendocrine tumor.

The phase IV clinical study analyzes which people have Myelosuppression when taking Afinitor. It is created by eHealthMe based on reports of 41,609 people who have side effects when taking Afinitor from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Myelosuppression?

Myelosuppression (a decrease in the production of blood cells) is found to be associated with 538 drugs and 208 conditions by eHealthMe. Check the latest studies of Myelosuppression.

On Jul, 21, 2026

41,609 people reported to have side effects when taking Afinitor.
Among them, 15 people (0.04%) have Myelosuppression.

Among these 15 people:

How long have people been on Afinitor when they have Myelosuppression? *

What is the gender of people who have Myelosuppression when taking Afinitor? *

female: 76.92 %
male: 23.08 %

What is the age of people who have Myelosuppression when taking Afinitor? *

What are other drugs people take besides Afinitor? *

Lutathera: 2 people, 13.33%
Combivent: 2 people, 13.33%
Sunitinib Malate: 1 person, 6.67%
Sandostatin: 1 person, 6.67%
Potassium Chloride: 1 person, 6.67%
Palonosetron Hydrochloride: 1 person, 6.67%
Octreotide Acetate: 1 person, 6.67%
Lanreotide Acetate: 1 person, 6.67%
Exemestane: 1 person, 6.67%
Diazoxide: 1 person, 6.67%

What are other side effects people have besides Myelosuppression? *

Malignant Neoplasm Progression (cancer tumour came back): 3 people, 20.00%
Thrombocytopenia (decrease of platelets in blood): 3 people, 20.00%
Anaemia (lack of blood): 3 people, 20.00%
Tumor Marker Increased: 2 people, 13.33%
Metastases To Liver (cancer spreads to liver): 2 people, 13.33%
Blood Disorder: 2 people, 13.33%
Constipation: 2 people, 13.33%
Flank Pain (a distressing sensation experienced around the lower back and the upper abdomen): 2 people, 13.33%
White Blood Cell Count Decreased: 2 people, 13.33%
Urinary Tract Obstruction: 2 people, 13.33%

What are the existing conditions these people have? *

Pancreatic Neuroendocrine Tumor: 3 people, 20.00%
Small Intestine Carcinoma (cancer tumour of small intestine): 1 person, 6.67%
Neuroendocrine Tumor: 1 person, 6.67%
Insulinoma (tumour of the pancreas that is derived from beta cells and secretes insulin): 1 person, 6.67%
Hypoglycemia (low blood sugar): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and have Myelosuppression?

- Check whether Myelosuppression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afinitor:

Afinitor (41,680 reports)

Myelosuppression treatments and more:

Myelosuppression (18,470 reports)

Browse all side effects of Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Myelosuppression:

Myelosuppression (538 drugs)

Browse all the conditions that are associated with Myelosuppression:

Myelosuppression (208 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.